Over half of patients had moderate or worse lung function at COPD diagnosis.1 *
WITH THE DUAL ACTION OF ANORO TO MAXIMIZE BRONCHODILATION VERSUS SPIRIVA HANDIHALER2-4
Defined as statistically significant improvements in lung function vs SPIRIVA HANDIHALER in two 24-week, randomized, blinded studies in patients with COPD. In a separate study versus SPIRIVA HANDIHALER, statistical significance cannot be inferred.3,4
*In a subset (n=366) of a managed-care population with a coded diagnosis of COPD severity based on GOLD stages 2 to 41
ANORO was studied in patients with moderate or worse COPD.
Get your patients started with ANORO
Download and send a savings coupon offer for ANORO* to your eligible patients